Insmed Incorporated INSM | NASDAQ
Next Earnings: Aug 06, 2025
Company Overview:
5.7 Year INSM Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
INSM Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for INSM
Based on past 5.7-year performance, here are INSM growth metrics:
Share price CAGR of +34.39%
Dividend CAGR of +0%
Using INSM CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| INSM (DRIP) | INSM - No DRIP | |
|---|---|---|
| Current Price | $98.67 | $98.67 |
| Start Shares | 101.35 | 101.35 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 101.35 | 101.35 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $1,411.09 | $98.67 |
| Total Dividends | $0 | $0 |
| Final Value | $143,011 | $10,000 |
NOTE: Above numbers are our estimate based on INSM's Dividend and Price CAGR over past 5.7 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Insmed Incorporated (INSM) had its IPO on 2000-06-01, and is trader on NASDAQ stock exchange.
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
INSM website: https://www.insmed.com
